[go: up one dir, main page]

MX2024002238A - Anticuerpos anti-ccr8 y uso de los mismos. - Google Patents

Anticuerpos anti-ccr8 y uso de los mismos.

Info

Publication number
MX2024002238A
MX2024002238A MX2024002238A MX2024002238A MX2024002238A MX 2024002238 A MX2024002238 A MX 2024002238A MX 2024002238 A MX2024002238 A MX 2024002238A MX 2024002238 A MX2024002238 A MX 2024002238A MX 2024002238 A MX2024002238 A MX 2024002238A
Authority
MX
Mexico
Prior art keywords
antigen
ccr8 antibodies
binding fragments
ccr8
antibodies
Prior art date
Application number
MX2024002238A
Other languages
English (en)
Inventor
Liang Schweizer
Francisco Adrian
Julie Prigent
Nicola Arturo Aldo Beltraminelli
Sami Ellouze
Yun - Yueh LU
Ross Bane Fulton
Original Assignee
Hifibio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hifibio Inc filed Critical Hifibio Inc
Publication of MX2024002238A publication Critical patent/MX2024002238A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/5758—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)

Abstract

Anticuerpos anti-CCR8 y fragmentos de unión a antígeno de los mismos se describen en la presente. También se describen en el presente documento ácidos nucleicos que codifican los anticuerpos anti-CCR8 y fragmentos de unión a antígeno de los mismos, las composiciones que comprenden los anticuerpos anti-CCR8 y fragmentos de unión a antígeno de los mismos, y métodos de producción y uso de los anticuerpos anti-CCR8 y fragmentos de unión a antígeno de los mismos para tratar o prevenir el cáncer en un sujeto que los necesite.
MX2024002238A 2021-08-20 2022-08-19 Anticuerpos anti-ccr8 y uso de los mismos. MX2024002238A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021113913 2021-08-20
PCT/CN2022/113739 WO2023020621A1 (en) 2021-08-20 2022-08-19 Anti-ccr8 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2024002238A true MX2024002238A (es) 2024-04-29

Family

ID=85239303

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024002238A MX2024002238A (es) 2021-08-20 2022-08-19 Anticuerpos anti-ccr8 y uso de los mismos.

Country Status (10)

Country Link
US (1) US20250019451A1 (es)
EP (1) EP4388009A4 (es)
JP (1) JP2024531409A (es)
KR (1) KR20240046533A (es)
CN (1) CN118176210A (es)
AU (1) AU2022331786A1 (es)
CA (1) CA3225986A1 (es)
IL (1) IL310938A (es)
MX (1) MX2024002238A (es)
WO (1) WO2023020621A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022552122A1 (en) 2020-02-14 2024-01-29 Jounce Therapeutics Inc Antibodies and fusion proteins that bind to ccr8 and uses thereof
JP2025527535A (ja) 2022-08-19 2025-08-22 ファイブロジェン，インコーポレイテッド 抗ｃｃｒ８抗体およびその使用
WO2024076514A1 (en) * 2022-10-02 2024-04-11 Remd Biotherapeutics, Inc. C-c chemokine receptor type 8 (ccr8) antagonist antibodies
WO2024248037A1 (ja) 2023-05-30 2024-12-05 塩野義製薬株式会社 Ｃｃｒ８を抗原として認識する二重特異性抗体
CN121358773A (zh) * 2023-06-12 2026-01-16 南京蓬勃生物科技有限公司 结合人ccr8的抗体及其用途
AU2024297761A1 (en) * 2023-07-07 2026-01-22 Qilu Pharmaceutical Co., Ltd. Pharmaceutical preparation of anti-human ccr8 monoclonal antibody and use thereof
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof
CN119371535B (zh) * 2024-09-20 2025-07-11 百济神州(上海)生物科技有限公司 抗ccr8抗体及其用途
CN119841954B (zh) * 2025-03-12 2025-11-04 上海百英生物科技股份有限公司 一种抗人ccr8单克隆抗体及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044756A2 (en) * 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
JP6894086B2 (ja) * 2018-12-27 2021-06-23 塩野義製薬株式会社 新規抗ｃｃｒ８抗体
WO2021142002A1 (en) * 2020-01-06 2021-07-15 Vaccinex, Inc. Anti-ccr8 antibodies and uses thereof
PH12022552122A1 (en) * 2020-02-14 2024-01-29 Jounce Therapeutics Inc Antibodies and fusion proteins that bind to ccr8 and uses thereof
TW202216771A (zh) * 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體

Also Published As

Publication number Publication date
KR20240046533A (ko) 2024-04-09
JP2024531409A (ja) 2024-08-29
CN118176210A (zh) 2024-06-11
AU2022331786A1 (en) 2024-04-04
US20250019451A1 (en) 2025-01-16
EP4388009A4 (en) 2025-07-09
WO2023020621A1 (en) 2023-02-23
IL310938A (en) 2024-04-01
CA3225986A1 (en) 2023-02-23
EP4388009A1 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
MX2024002238A (es) Anticuerpos anti-ccr8 y uso de los mismos.
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
ZA202006318B (en) Anti-dll3 antibodies and uses thereof
PH12020550214A1 (en) Antibodies specific to cd47 and pd-l1
CR20230581A (es) Anticuerpos anti-CCR8 y usos de los mismos
SA519402358B1 (ar) Ccr7 مترافقات عقار جسم مضاد لـ
PH12021552790A1 (en) Materials and methods for modulating t cell mediated immunity
MX2022010664A (es) Materiales y métodos para modular una respuesta inmunitaria.
PH12022553035A1 (en) Anti-phf-tau antibodies and uses thereof
ZA202302392B (en) Antibodies against ilt2 and use thereof
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
MX2023011340A (es) Anticuerpos humanizados contra el filamento helicoidal emparejado tau y usos de estos.
MX2021015766A (es) Nuevos antigenos y metodos contra el cancer.
MX2023002948A (es) Métodos y composiciones para modular la inmunidad mediada por cadena beta.
MX2021004454A (es) Anticuerpos anti-sinucleina.
MX2023011339A (es) Anticuerpos anti-tau y usos de estos.
MX2024011805A (es) Nuevos anticuerpos anti-fgfr2
MX2022013920A (es) Anticuerpos anti-antigeno asociado con tumor y usos de los mismos.
AU2018345715A8 (en) DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer
MX2022007513A (es) Anticuerpos biespecificos con cisteinas intercatenarias apareadas alternativamente y sus usos.
MX2023009211A (es) Anticuerpos biespecificos con pares de carga y usos de los mismos.
MX2024009326A (es) Anticuerpos anti-btla y usos de los mismos en el tratamiento del cancer.
WO2021043810A8 (en) Anti-fucosyl-gm1 antibodies